Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. To the extent this release contains historical non-GAAP financial measures, we have also provided corresponding GAAP financial measures for comparative purposes.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage preclinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbo
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
3. Pharmacyclics, Inc. Rights Offering Oversubscribed
4. Pharmacyclics Announces Subscription Price for Rights Offering
5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
9. Pharmacyclics Secures $5.0 Million in Debt Financing
10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... REDWOOD CITY, Calif. , Dec. 19, 2014 ... , USA) announced today that they have been ... Technologies 1,2 is a privately held company that ... processing of next generation sequencing (NGS) data for the ... into the Roche Sequencing Unit, and will continue to ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... decision last week to merge its Imaging and Printing Group ... Systems Group (IPSG) is a major milestone in HPs journey ... combining these two units, HP has a unified and convincing ... may be the key that turns HPs consumer message into ...
... researchers will show off developments in games that offer real-world ... ,The Academic Advanced Distributed Learning Co-Laboratory , WTN and ... how Games are Shaping Business and Learning, which will center ... applied to the workforce. , ,The video game industry has ...
... Business is booming again at the University of Wisconsin-Madisons ... job-seekers. , ,This is the best hiring situation weve seen ... associate director of ECS . Fall 2004 recruiting was ... are expected to attend Career Connection, the colleges spring job ...
Cached Biology Technology:HP charges toward the living room 2HP charges toward the living room 3Businesses and educators to preview video games for training 2Businesses and educators to preview video games for training 3Companies recruiting more UW engineering students 2Companies recruiting more UW engineering students 3Companies recruiting more UW engineering students 4
(Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... silver lining for threatened species of grizzly bears in ... bears in Alberta,s Rocky Mountain region, University of Alberta ... temperatures and easier access to food associated with forest ... known to increase the chances of successful reproduction for ...
... , October 28, 2013 Danish ... first truly affordable eye tracking device, and promise free ... cases.      (Photo: http://photos.prnewswire.com/prnh/20131028/648669 ) ... their $99 eye tracker on 29 October at TechCrunch ...
... project officially started at the beginning of October. The goal ... years so that Continental can manufacture tires made from dandelion ... research department of the automotive supplier built a pilot facility ... the ton. At the same time, they cultivate several hectares ...
Cached Biology News:Climate change has silver lining for grizzlies 2The Eye Tribe Demo $99 Eye Tracker at TechCrunch Disrupt Europe and Awards Great Ideas With Free Eye Trackers! 2The Eye Tribe Demo $99 Eye Tracker at TechCrunch Disrupt Europe and Awards Great Ideas With Free Eye Trackers! 3Fraunhofer and Continental come together when the dandelion rubber meets the road 2Fraunhofer and Continental come together when the dandelion rubber meets the road 3
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: